Fig. 5

PCSK9 inhibition triggers anti-tumor effects in gastric cancer model (A) Schematic of PCSK9i treatment in MFC challenged syngeneic gastric cancer model. 615-line mice are s.c. injected with 10⁶ MFC cells (n = 6 per group) and treated i.p. with PCSK9i (5 mg/kg) or DMSO every other day for 18 days. Mice were sacrificed via cervical dislocation at the treatment endpoint, and (B) tumors were removed for analysis. (C) Tumor weight and (D) volumes of MFC-bearing 615-line mice treated with PCSK9i or DMSO (n = 6 per group). (E) Weights of 614-line mice in two groups. (F-G) The proportions of tumor-infiltrating MHC-II⁺/CD11c⁺ cells, MHC-II⁺ tumor cells, and CD8⁺/CD3⁺ cells were determined by flow cytometry. (H) The proportions of tumor-infiltrating CD25⁺/CD8⁺ cells, CD69⁺/CD8⁺ cells, and CD107a⁺/CD8⁺ cells were assessed by flow cytometry. Data with error bars are shown as mean ± SEM